Short and tall stature: A new paradigm emerges

Nature Reviews Endocrinology

Volumn 11, Issue 12, 2015, Pages 736-746

  Baron, Jeffrey ^a   Sävendahl, Lars ^b   De Luca, Francesco ^c   Dauber, Andrew ^d   Phillip, Moshe ^e   Wit, Jan M ^f   Nilsson, Ola ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ATRIAL NATRIURETIC FACTOR RECEPTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR 2; BONE MORPHOGENETIC PROTEIN; CYTOKINE; ESTROGEN; FIBROBLAST GROWTH FACTOR; GLUCOCORTICOID; GROWTH HORMONE; NATRIURETIC PEPTIDE TYPE C; PARATHYROID HORMONE RELATED PROTEIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; THYROID HORMONE; UNCLASSIFIED DRUG; HUMAN GROWTH HORMONE;

BODY HEIGHT; BONE GROWTH; CARTILAGE CELL; CHILD GROWTH; CHONDROGENESIS; COPY NUMBER VARIATION; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; GROWTH PLATE; HORMONAL THERAPY; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; REVIEW; SHORT STATURE; TALL STATURE; ANIMAL; GENE DOSAGE; GENETICS; GROWTH DISORDER; PHYSIOLOGY;

ANIMALS; BODY HEIGHT; GENE DOSAGE; GROWTH DISORDERS; GROWTH PLATE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 84947618234     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.165     Document Type: Review

References (149)

1. Rosenfeld, R. G. The molecular basis of idiopathic short stature. Growth Horm. IGF Res. 15 (Suppl. A), S3-S5 (2005).
2. Hindmarsh, P. C. & Brook, C. G. Short stature and growth hormone deficiency. Clin. Endocrinol. (Oxf.). 43, 133-142 (1995).
3. Zadik, Z., Chalew, S. A., Zung, A., Lieberman, E. & Kowarski, A. A. Short stature: new challenges in growth hormone therapy. J. Pediatr. Endocrinol. 6, 303-310 (1993).
4. Savage, M. O., Burren, C. P. & Rosenfeld, R. G. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin. Endocrinol. (Oxf.). 72, 721-728 (2010).
5. Daughaday, W. H. Growth hormone axis overview-somatomedin hypothesis. Pediatr. Nephrol. 14, 537-540 (2000).
6. Furlanetto, R. W., Underwood, L. E., Van Wyk, J. J. & D'Ercole, A. J. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J. Clin. Invest. 60, 648-657 (1977).
7. Roth, J., Glick, S. M., Yalow, R. S. & Berson, S. A. The influence of blood glucose on the plasma concentration of growth hormone. Diabetes 13, 355-361 (1964).
8. Cooke, D. S., Divall, S. A. & Radovick, S. in Williams Textbook of Endocrinology 12th edn Ch. 24 (eds Melmed, S., Williams, R. H., Larsen, P. R. & Kronenberg, H.) 959 (Elsevier/Saunders, 2011).
9. Wit, J. M. et al. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm. IGF Res. 18, 89-110 (2008).
10. Codner, E. et al. Relationship between serum growth hormone binding protein levels and height in young men. J. Pediatr. Endocrinol. Metab. 13, 887-892 (2000).
11. Gill, M. S. et al. Regular fluctuations in growth hormone (GH) release determine normal human growth. Growth Horm. IGF Res. 9, 114-122 (1999).
12. Sisley, S., Trujillo, M. V., Khoury, J. & Backeljauw, P. Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J. Pediatr. 163, 1045-1051 (2013).
13. Dauber, A., Rosenfeld, R. G. & Hirschhorn, J. N. Genetic evaluation of short stature. J. Clin. Endocrinol. Metab. 99, 3080-3092 (2014).
14. Stanley, T. L., Levitsky, L. L., Grinspoon, S. K. & Misra, M. Effect of body mass index on peak growth hormone response to provocative testing in children with short stature. J. Clin. Endocrinol. Metab. 94, 4875.4881 (2009).
15. Marin, G. et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J. Clin. Endocrinol. Metab. 79, 537.541 (1994).
16. Rose, S. R. et al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N. Engl. J. Med. 319, 201.207 (1988).
17. Rosenbloom, A. L. Idiopathic short stature: conundrums of definition and treatment. Int. J. Pediatr. Endocrinol. 2009, 470378 (2009).
18. Wudy, S. A. et al. Children with idiopathic short stature are poor eaters and have decreased body mass index. Pediatrics 116, e52.e57 (2005).
19. Rosenbloom, A. L. Is there a role for recombinant insulin-like growth factor.I in the treatment of idiopathic short stature? Lancet 368, 612.616 (2006).
20. Olney, R. C. et al. Heterozygous mutations in natriuretic peptide receptor.B (NPR2) are associated with short stature. J. Clin. Endocrinol. Metab. 91, 1229.1232 (2006).
21. Kronenberg, H. M. Developmental regulation of the growth plate. Nature 423, 332.336 (2003).
22. Nilsson, O., Marino, R., De Luca, F., Phillip, M. & Baron, J. Endocrine regulation of the growth plate. Horm. Res. 64, 157.165 (2005).
23. Lango Allen, H. et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467, 832.838 (2010).
24. Mushtaq, T., Bijman, P., Ahmed, S. F. & Farquharson, C. Insulin-like growth factor.I augments chondrocyte hypertrophy and reverses glucocorticoid-mediated growth retardation in fetal mice metatarsal cultures. Endocrinology 145, 2478.2486 (2004).
25. Baron, J., Huang, Z., Oerter, K. E., Bacher, J. D. & Cutler, G. B. Jr. Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. Am. J. Physiol. 263, E489.E492 (1992).
26. Rivkees, S. A., Danon, M. & Herrin, J. Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure. J. Pediatr. 125, 322.325 (1994).
27. Wang, L., Shao, Y. Y. & Ballock, R. T. Thyroid hormone interacts with the Wnt/A-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J. Bone Miner. Res. 22, 1988.1995 (2007).
28. Barnard, J. C. et al. Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis. Endocrinology 146, 5568.5580 (2005).
29. Raz, P., Nasatzky, E., Boyan, B. D., Ornoy, A. & Schwartz, Z. Sexual dimorphism of growth plate prehypertrophic and hypertrophic chondrocytes in response to testosterone requires metabolism to dihydrotestosterone (DHT) by steroid 5. reductase type 1. J. Cell. Biochem. 95, 108.119 (2005).
30. Ren, S. G. et al. Direct administration of testosterone increases rat tibial epiphyseal growth plate width. Acta Endocrinol. 121, 401.405 (1989).
31. Borjesson, A. E. et al. The role of estrogen receptor in growth plate cartilage for longitudinal bone growth. J. Bone Miner. Res. 25, 2690.2700 (2010).
32. Chagin, A. S., Chrysis, D., Takigawa, M., Ritzen, E. M. & Savendahl, L. Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis. J. Endocrinol. 188, 193.203 (2006).
33. Mazziotti, G. & Giustina, A. Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol. 9, 265.276 (2013).
34. Benker, G. et al. TSH secretion in Cushings syndrome: relation to glucocorticoid excess, diabetes, goitre, and the sick euthyroid syndrome. Clin. Endocrinol. 33, 777.786 (1990).
35. Nilsson, O. et al. Evidence that estrogen hastens epiphyseal fusion and cessation of longitudinal bone growth by irreversibly depleting the number of resting zone progenitor cells in female rabbits. Endocrinology 155, 2892.2899 (2014).
36. Weise, M. et al. Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc. Natl Acad. Sci. USA 98, 6871.6876 (2001).
37. Quaynor, S. D. et al. Delayed puberty and estrogen resistance in a woman with estrogen receptor variant. N. Engl. J. Med. 369, 164.171 (2013).
38. Smith, E. P. et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331, 1056.1061 (1994).
39. Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C. & Qin, K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80, 3689.3698 (1995).
40. Dunkel, L. Update on the role of aromatase inhibitors in growth disorders. Horm. Res. 71 (Suppl. 1), 57.63 (2009).
41. Wit, J. M., Hero, M. & Nunez, S. B. Aromatase inhibitors in pediatrics. Nat. Rev. Endocrinol. 8, 135.147 (2012).
42. van der Eerden, B. C., Lowik, C. W., Wit, J. M. & Karperien, M. Expression of estrogen receptors and enzymes involved in sex steroid metabolism in the rat tibia during sexual maturation. J. Endocrinol. 180, 457.467 (2004).
43. Fernandez-Vojvodich, P., Palmblad, K., Karimian, E., Andersson, U. & Savendahl, L. Pro-inflammatory cytokines produced by growth plate chondrocytes may act locally to modulate longitudinal bone growth. Horm. Res. Paediatr. 77, 180.187 (2012).
44. Savendahl, L. The effect of acute and chronic stress on growth. Sci. Signal 5, 9 (2012).
45. Sederquist, B., Fernandez-Vojvodich, P., Zaman, F. & Savendahl, L. Impact of inflammatory cytokines on longitudinal bone growth. J. Mol. Endocrinol. 53, T35.T44 (2014).
46. MacRae, V. E., Farquharson, C. & Ahmed, S. F. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol. 189, 319.328 (2006).
47. Martensson, K., Chrysis, D. & Savendahl, L. Interleukin-1A and TNF-act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J. Bone Miner. Res. 19, 1805.1812 (2004).
48. Phillip, M., Moran, O. & Lazar, L. Growth without growth hormone. J. Pediatr. Endocrinol. Metab. 15 (Suppl. 5), 1267.1272 (2002).
49. Couto-Silva, A. C. et al. Final height and gonad function after total body irradiation during childhood. Bone Marrow Transplant. 38, 427.432 (2006).
50. Stokes, I. A., Aronsson, D. D., Dimock, A. N., Cortright, V. & Beck, S. Endochondral growth in growth plates of three species at two anatomical locations modulated by mechanical compression and tension. J. Orthop. Res. 24, 1327.1334 (2006).
51. Stokes, I. A., Mente, P. L., Iatridis, J. C., Farnum, C. E. & Aronsson, D. D. Enlargement of growth plate chondrocytes modulated by sustained mechanical loading. J. Bone Joint Surg. Am. 84.A, 1842.1848 (2002).
52. Lykissas, M. G. et al. Guided growth for the treatment of limb length discrepancy: A comparative study of the three most commonly used surgical techniques. J. Pediatr. Orthop. B 22, 311.317 (2013).
53. Caine, D., Howe, W., Ross, W. & Bergman, G. Does repetitive physical loading inhibit radial growth in female gymnasts? Clin. J. Sport Med. 7, 302.308 (1997).
54. Hung, I. H., Yu, K., Lavine, K. J. & Ornitz, D. M. FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Dev. Biol. 307, 300.313 (2007).
55. Lazarus, J. E., Hegde, A., Andrade, A. C., Nilsson, O. & Baron, J. Fibroblast growth factor expression in the postnatal growth plate. Bone 40, 577.586 (2007).
56. Liu, Z., Lavine, K. J., Hung., I. H. & Ornitz, D. M. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev. Biol. 302, 80.91 (2007).
57. Mancilla, E. E., De Luca, F., Uyeda, J. A., Czerwiec, F. S. & Baron, J. Effects of fibroblast growth factor.2 on longitudinal bone growth. Endocrinology 139, 2900.2904 (1998).
58. De Luca, F. et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein.2. Endocrinology 142, 430.436 (2001).
59. Nilsson, O. et al. Gradients in bone morphogenetic protein-related gene expression across the growth plate. J. Endocrinol. 193, 75.84 (2007).
60. Pogue, R. & Lyons, K. BMP signaling in the cartilage growth plate. Curr. Top. Dev. Biol. 76, 1.48 (2006).
61. Andrade, A. C., Nilsson, O., Barnes, K. M. & Baron, J. Wnt gene expression in the post-natal growth plate: regulation with chondrocyte differentiation. Bone 40, 1361.1369 (2007).
62. Kuss, P. et al. Regulation of cell polarity in the cartilage growth plate and perichondrium of metacarpal elements by HOXD13 and WNT5A. Dev. Biol. 385, 83.93 (2014).
63. Lui, J. C., Nilsson, O. & Baron, J. Recent insights into the regulation of the growth plate. J. Mol. Endocrinol. 53, T1.T9 (2014).
64. Vajo, Z., Francomano, C. A. & Wilkin, D. J. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev. 21, 23.39 (2000).
65. Kant, S. G. et al. A novel variant of FGFR3 causes proportionate short stature. Eur. J. Endocrinol. 172, 763.770 (2015).
66. Toydemir, R. M. et al. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am. J. Hum. Genet. 79, 935.941 (2006).
67. Makrythanasis, P. et al. A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly. Hum. Mutat. 35, 959.963 (2014).
68. Yasoda, A. et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat. Med. 10, 80.86 (2004).
69. Sahni, M. et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT.1 pathway. Genes Dev. 13, 1361.1366 (1999).
70. Baron, J. et al. Induction of growth plate cartilage ossification by basic fibroblast growth factor. Endocrinology 135, 2790.2793 (1994).
71. Chen, L. et al. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest. 104, 1517.1525 (1999).
72. Minina, E., Kreschel, C., Naski, M. C., Ornitz, D. M. & Vortkamp, A. Interaction of FGF Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev. Cell 3, 439.449 (2002).
73. Foldynova-Trantirkova, S., Wilcox, W. R. & Krejci, P. Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat. 33, 29.41 (2012).
74. Xie, Y., Zhou, S., Chen, H., Du, X. & Chen, L. Recent research on the growth plate: advances in fibroblast growth factor signaling in growth plate development and disorders. J. Mol. Endocrinol. 53, T11.T34 (2014).
75. Klopocki, E. et al. Deletion and point mutations of PTHLH cause brachydactyly type E. Am. J. Hum. Genet. 86, 434.439 (2010).
76. Chusho, H. et al. Dwarfism and early death in mice lacking C.type natriuretic peptide. Proc. Natl Acad. Sci. USA 98, 4016.4021 (2001).
77. Mericq, V., Uyeda, J. A., Barnes, K. M., De Luca, F. & Baron, J. Regulation of fetal rat bone growth by C.type natriuretic peptide and cGMP. Pediatr. Res. 47, 189.193 (2000).
78. Pejchalova, K., Krejci, P. & Wilcox, W. R. C.natriuretic peptide: an important regulator of cartilage. Mol. Genet. Metab. 92, 210.215 (2007).
79. Bartels, C. F. et al. Mutations in the transmembrane natriuretic peptide receptor NPR.B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am. J. Hum. Genet. 75, 27.34 (2004).
80. Amano, N. et al. Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature. J. Clin. Endocrinol. Metab. 99, E713.E718 (2014).
81. Vasques, G. A. et al. Heterozygous mutations in natriuretic peptide receptor.B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. J. Clin. Endocrinol. Metab. 98, E1636.E1644 (2013).
82. Wang, S. R. et al. Heterozygous mutations in natriuretic peptide receptor.B (NPR2) gene as a cause of short stature. Hum. Mutat. 36, 474.481 (2015).
83. Bocciardi, R. et al. Overexpression of the C.type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum. Mutat. 28, 724.731 (2007).
84. Moncla, A. et al. A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype. Hum. Mutat. 28, 1183.1188 (2007).
85. Hannema, S. E. et al. An activating mutation in the kinase homology domain of the natriuretic peptide receptor.2 causes extremely tall stature without skeletal deformities. J. Clin. Endocrinol. Metab. 98, E1988.E1998 (2013).
86. Miura, K. et al. Overgrowth syndrome associated with a gain.of.function mutation of the natriuretic peptide receptor 2 (NPR2) gene. Am. J. Med. Genet. A 164A, 156.163 (2014).
87. Teixeira, C. C., Agoston, H. & Beier, F. Nitric oxide, C.type natriuretic peptide and cGMP as regulators of endochondral ossification. Dev. Biol. 319, 171.178 (2008).
88. Miyazawa, T. et al. Cyclic GMP-dependent protein kinase II plays a critical role in C.type natriuretic peptide-mediated endochondral ossification. Endocrinology 143, 3604.3610 (2002).
89. Krejci, P. et al. Interaction of fibroblast growth factor and C.natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J. Cell Sci. 118, 5089.5100 (2005).
90. Yasoda, A. et al. Systemic administration of C.type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 150, 3138.3144 (2009).
91. Neptune, E. R. et al. Dysregulation of TGF-A activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407.411 (2003).
92. Dietz, H. C. & Pyeritz, R. E. Mutations in the human gene for fibrillin.1 (FBN1) in the Marfan syndrome and related disorders. Hum. Mol. Genet. 4, 1799.1809 (1995).
93. Brooke, B. S. et al. Angiotensin II blockade and aortic-root dilation in Marfans syndrome. N. Engl. J. Med. 358, 2787.2795 (2008).
94. Koziel, L., Kunath, M., Kelly, O. G. & Vortkamp, A. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev. Cell 6, 801.813 (2004).
95. Jochmann, K., Bachvarova, V. & Vortkamp, A. Heparan sulfate as a regulator of endochondral ossification and osteochondroma development. Matrix Biol. 35, 239.247 (2014).
96. Warman, M. L. et al. A type X collagen mutation causes Schmid metaphyseal chondrodysplasia. Nat. Genet. 5, 79.82 (1993).
97. Tompson, S. W. et al. A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C.type lectin domain of aggrecan. Am. J. Hum. Genet. 84, 72.79 (2009).
98. Gleghorn, L., Ramesar, R., Beighton, P. & Wallis, G. A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis. Am. J. Hum. Genet. 77, 484.490 (2005).
99. Stattin, E. L. et al. A missense mutation in the aggrecan C.type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. Am. J. Hum. Genet. 86, 126.137 (2010).
100. Nilsson, O. et al. Short stature, accelerated bone maturation, and early growth cessation due to heterozygous aggrecan mutations. J. Clin. Endocrinol. Metab. 99, E1510.E1518 (2014).
101. Lauing, K. L. et al. Aggrecan is required for growth plate cytoarchitecture and differentiation. Dev. Biol. 396, 224.236 (2014).
102. Watanabe, H. & Yamada, Y. Chondrodysplasia of gene knockout mice for aggrecan and link protein. Glycoconj. J. 19, 269.273 (2002).
103. Xu, T. et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 20, 78.82 (1998).
104. Cain, S. A., McGovern, A., Baldwin, A. K., Baldock, C. & Kielty, C. M. Fibrillin.1 mutations causing Weill-Marchesani syndrome and acromicric and geleophysic dysplasias disrupt heparan sulfate interactions. PLoS ONE 7, e48634 (2012).
105. Akiyama, H. & Lefebvre, V. Unraveling the transcriptional regulatory machinery in chondrogenesis. J. Bone Miner. Metab. 29, 390.395 (2011).
106. Marchini, A. et al. The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes. J. Biol. Chem. 279, 37103.37114 (2004).
107. Malaquias, A. C. et al. The sitting height/height ratio for age in healthy and short individuals and its potential role in selecting short children for SHOX analysis. Horm. Res. Paediatr. 80, 449.456 (2013).
108. Binder, G. Short stature due to SHOX deficiency: genotype, phenotype, and therapy. Horm. Res. Paediatr. 75, 81.89 (2011).
109. Ottesen, A. M. et al. Increased number of sex chromosomes affects height in a nonlinear fashion: A study of 305 patients with sex chromosome aneuploidy. Am. J. Med. Genet. A 152A, 1206.12 (2010).
110. Cseh, B., Doma, E. & Baccarini, M. RAF neighborhood: Protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett. 588, 2398.2406 (2014).
111. Lee, B. H. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J. Pediatr. 159, 1029.1035 (2011).
112. Stevenson, D. A. & Yang, F. C. The musculoskeletal phenotype of the RASopathies. Am. J. Med. Genet. C Semin. Med. Genet. 157C, 190.103 (2011).
113. Visser, R., Kant, S. G., Wit, J. M. & Breuning, M. H. Overgrowth syndromes:from classical to new. Pediatr. Endocrinol. Rev. 6, 375.394 (2009).
114. Wu, S., Fadoju, D., Rezvani, G. & De Luca, F. Stimulatory effects of insulin-like growth factor.I on growth plate chondrogenesis are mediated by nuclear factor-B p65. J. Biol. Chem. 283, 34037.34044 (2008).
115. Wu, S. et al. Growth hormone and insulin-like growth factor I insensitivity of fibroblasts isolated from a patient with an IB mutation. J. Clin. Endocrinol. Metab. 95, 1220.1228 (2010).
116. Klingseisen, A. & Jackson, A. P. Mechanisms and pathways of growth failure in primordial dwarfism. Genes Dev. 25, 2011.2024 (2011).
117. Huber, C. et al. Identification of mutations in CUL7 in 3.M syndrome. Nat. Genet. 37, 1119.1124 (2005).
118. Hanson, D. et al. The primordial growth disorder 3.M syndrome connects ubiquitination to the cytoskeletal adaptor OBSL1. Am. J. Hum. Genet. 84, 801.806 (2009).
119. Hanson, D. et al. Exome sequencing identifies CCDC8 mutations in 3.M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth. Am. J. Hum. Genet. 89, 148.153 (2011).
120. Yan, J. et al. The 3M complex maintains microtubule and genome integrity. Mol. Cell 54, 791.804 (2014).
121. Rauch, A. et al. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science 319, 816.819 (2008).
122. Bicknell, L. S. et al. Mutations in the pre-replication complex cause Meier-Gorlin syndrome. Nat. Genet. 43, 356.359 (2011).
123. Guernsey, D. L. et al. Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome. Nat. Genet. 43, 360.364 (2011).
124. Knoch, J., Kamenisch, Y., Kubisch, C. & Berneburg, M. Rare hereditary diseases with defects in DNA-repair. Eur. J. Dermatol. 22, 443.455 (2012).
125. Tatton-Brown, K. et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat. Genet. 46, 385.388 (2014).
126. Gibson, W. T. et al. Mutations in EZH2 cause Weaver syndrome. Am. J. Hum. Genet. 90, 110.118 (2012).
127. Canton, A. P. et al. Genome-wide screening of copy number variants in children born small for gestational age reveals several candidate genes involved in growth pathways. Eur. J. Endocrinol. 171, 253-262 (2014).
128. van Duyvenvoorde, H. A. et al. Copy number variants in patients with short stature. Eur. J. Hum. Genet. 22, 602-609 (2014).
129. Zahnleiter, D. et al. Rare copy number variants are a common cause of short stature. PLoS Genet. 9, e1003365 (2013).
130. Wood, A. R. et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat. Genet. 46, 1173-1186 (2014).
131. Lui, J. C. et al. Synthesizing genome-wide association studies and expression microarray reveals novel genes that act in the human growth plate to modulate height. Hum. Mol. Genet. 21, 5193-5201 (2012).
132. Liu, F. et al. Common DNA variants predict tall stature in Europeans. Hum. Genet. 133, 587-597 (2014).
133. Wit, J. M., Ranke, M. B. & Kelnar, C. J. H. The ESPE classification of paediatric endocrine diagnoses. Horm. Res. 68 (Suppl. 2), 1-120 (2007).
134. Chitty, L. S. et al. New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma. Ultrasound Obstet. Gynecol. 37, 283-289 (2011).
135. Chitty, L. S. Safe, accurate, prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA. Prenat. Diagn. 33, 416-423 (2013).
136. Bober, M. B., Bellus, G. A., Nikkel, S. M. & Tiller, G. E. Hypochondroplasia. GeneReviews® [online], http://www.ncbi.nlm.nih.gov/books/NBK1477/(1999).
137. Cohen, M. M. Jr. Some chondrodysplasias with short limbs: molecular perspectives. Am. J. Med. Genet. 112, 304-313 (2002).
138. Miyake, N. et al. PAPSS2 mutations cause autosomal recessive brachyolmia. J. Med. Genet. 49, 533-538 (2012).
139. Oostdijk, W. et al. PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation-in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. J. Clin. Endocrinol. Metab. 100, E672-E680 (2015).
140. Roberts, A. E., Allanson, J. E., Tartaglia, M. & Gelb, B. D. Noonan syndrome. Lancet 381, 333-342 (2013).
141. Wang, S. R. et al. Large-scale pooled next-generation sequencing of 1077 genes to identify genetic causes of short stature. J. Clin. Endocrinol. Metab. 98, E1428-E1437 (2013).
142. Blum, W. F. et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J. Clin. Endocrinol. Metab. 92, 219-228 (2007).
143. Noordam, C., Van der Burgt, I., Sengers, R. C., Delemarre-van de Waal, H. A. & Otten, B. J. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial. Acta Paediatr. 90, 889-894 (2001).
144. Albertsson-Wikland, K. et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 4342-4350 (2008).
145. Leschek, E. W. et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: A randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 3140-3148 (2004).
146. Trivellin, G. et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N. Engl. J. Med. 371, 2363-2374 (2014).
147. Hunziker, E. B., Wagner, J. & Zapf, J. Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J. Clin. Invest. 93, 1078-1086 (1994).
148. Nilsson, O. et al. Growth plate senescence is associated with loss of DNA methylation. J. Endocrinol. 186, 241-249 (2005).
149. Wang, J., Zhou, J., Cheng, C. M., Kopchick, J. J. & Bondy, C. A. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J. Endocrinol. 180, 247-255 (2004).